Beta Bionics, Inc. (BBNX) total debt
Beta Bionics, Inc. (BBNX) carried total debt of $7.30M at the end of fiscal 2025 (December 31, 2025). That is 0.7% higher than the $7.26M of fiscal 2024. Figures as of 18 Nov 2026, 09:30 UTC, from Yahoo Finance.
Key facts
- Total debt, fiscal 2025
- $7.30M
- Change on fiscal 2024
- +0.7%
- Highest on record
- $7.30Mfiscal 2025
- Lowest on record
- $4.13Mfiscal 2022
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.
Beta Bionics, Inc. total debt, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $7.30M in fiscal 2025 and the lowest $4.13M in fiscal 2022.
Total debt was 0.0× shareholders' equity at the end of fiscal 2025.
Total debt by fiscal year
Beta Bionics, Inc. total debt, year by year
| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
|---|---|---|---|---|
| 2025 | $7.30M | 0.7% up | 0.0× | |
| 2024 | $7.26M | 71.8% up | — | |
| 2023 | $4.22M | 2.2% up | — | |
| 2022 | $4.13M | — | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
How to read it
Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.
Beta Bionics, Inc., figure by figure
- Beta Bionics, Inc. market cap
- Beta Bionics, Inc. revenue
- Beta Bionics, Inc. earnings
- Beta Bionics, Inc. earnings per share (EPS)
- Beta Bionics, Inc. P/E ratio
- Beta Bionics, Inc. P/S ratio
- Beta Bionics, Inc. P/B ratio
- Beta Bionics, Inc. free cash flow
- Beta Bionics, Inc. operating margin
- Beta Bionics, Inc. dividend
- Beta Bionics, Inc. shares outstanding
- Beta Bionics, Inc. cash on hand
- Beta Bionics, Inc. total assets
- Beta Bionics, Inc. return on equity (ROE)
- Beta Bionics, Inc. return on invested capital (ROIC)
Beta Bionics, Inc. (BBNX) overview: price, valuation and scorecard
Beta Bionics, Inc. total debt: questions and answers
How much debt does Beta Bionics, Inc. have?
Beta Bionics, Inc. (BBNX) carried total debt of $7.30M at the end of fiscal 2025 (December 31, 2025). That is 0.7% higher than the $7.26M of fiscal 2024.
What are the highest and lowest total debt figures on record for Beta Bionics, Inc.?
Across the 4 fiscal years on record (2022–2025), the highest was $7.30M in fiscal 2025 and the lowest $4.13M in fiscal 2022.
How does Beta Bionics, Inc.'s debt compare with its equity?
Total debt was 0.0× shareholders' equity at the end of fiscal 2025.
How is Beta Bionics, Inc.'s total debt calculated?
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative. For Beta Bionics, Inc. it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total debt
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Beta Bionics, Inc. (BBNX) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/BBNX/total-debt
Underlying data: Yahoo Finance.